| 摘要 |
The present invention relates to methods of treating movement disorders which comprise administering famotidine or a related compound to a subject in need of such treatment, wherein the motor disorder is selected from the group consisting of olivo-ponto-cerebellar atrophy, multi-system atrophy, Shy-Drager syndrome, kernicterus, Leigh's disease, cerebellar ataxias, neonatal hypoxemia syndromes, carbon monoxide poisoning, progressive supranuclear palsy, tardive dystonias, oculogyral crises, manganese poisoning, Wilson's Disease, Huntington's Disease, striatonigral degeneration, ingestion by the subject of phenothiazines, butyrophenones or reserpine, Alzheimer's Disease, normal pressure hydrocephalus, obstructive hydrocephalus, physiologic tremor, benign familial tremor, cerebellar tremor, rubral tremor, toxic tremor, metabolic tremor, senile tremor, chorea, ballism, athetosis, dystonia, tics, tardive dyskinesia, paroxysmal choreoathetosis, tonic spasm, akathisia, muscle rigidity, postural instability, bradykinesia, difficulty in initiating movements, muscle cramps, dyskinesias, myoclonus, and Creutzfeldt-Jacob Disease, and wherein the subject does not exhibit bradyphrenia. In preferred embodiments of the invention, the movement disorder is associated with an abnormality in basal ganglia structure or function. In a particularly preferred embodiment of the invention, the movement disorder is a component of Parkinson's Disease. The present invention is based, at least in part, on the discovery that Parkinson's Disease patients treated with famotidine reported improved motor function, diminished tremor, and decreased dyskinesias and "on/off" fluctuations in their response to conventional levodopa therapy.
|
